Soaring Demand Set to Propel Panic Disorders Market to $13.97 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Panic Disorders Market Through 2025?
The financial scope of the panic disorders market has experienced consistent expansion lately; specifically, projections indicate an increase from $10.73 billion recorded in 2024 to an anticipated $11.15 billion by 2025, reflecting a consistent yearly growth rate calculated at 3.9%. This upward trajectory observed in the past can be credited to several contributing factors, including the wider utilization of antidepressant pharmaceuticals, heightened societal recognition of mental well-being issues, escalating societal stress burdens, improved availability of care for psychological health, and refinements made to how these conditions are clinically defined.

What's the Projected Size of the Global Panic Disorders Market by 2029?
Anticipation for the panic disorders sector suggests a robust expansion trajectory ahead, with projections indicating the market value will reach close to $13.97 billion by the year 2029, reflecting a steady compound annual growth rate of 5.8% throughout the projection timeframe; this upward momentum is fueled by the introduction of novel drug therapies, the increasing availability of telepsychiatry, greater clinical attention directed at co-occurring conditions, worldwide initiatives aimed at enhancing mental well-being, the incorporation of pharmacogenomics into patient care strategies, and various public awareness campaigns, while key developments shaping this period encompass the adoption of digital mental health solutions, the utilization of remote care for managing panic disorder, advancements in pharmaceutical development, deeper exploration into the underlying neurobiology, and the integration of wearable devices for remote patient oversight.

View the full report here:
https://www.thebusinessresearchcompany.com/report/panic-disorders-global-market-report

Top Growth Drivers in the Panic Disorders Industry: What's Accelerating the Market?
The projected rise in individuals suffering from psychiatric conditions is anticipated to fuel the expansion of the panic disorder market moving ahead. Psychiatric disorders, which introduce disruptions to an individual's thought processes, emotional state, and social conduct, manifest sometimes as panic disorder or sudden, intense panic attacks. Management for those experiencing panic disorder within the psychiatric patient demographic generally incorporates multimodal strategies, encompassing pharmaceutical interventions, psychotherapy, and adjustments to daily living to lessen the severity of panic attacks, enhance the patient's general well-being, and equip them with effective coping mechanisms for their affliction. Illustratively, data from the State of Mental Health in America 2022 report, released in October 2022 by Mental Health America, a US non-profit focused on mental wellness advocacy, indicated that the count of psychiatric patients or adults diagnosed with any mental illness climbed to 49,564,000 in 2022, constituting 19.86% of the entire US populace, up from 47,132,000, or 19.00%, in 2021. Consequently, this escalation in the volume of psychiatric patients is set to serve as a catalyst for progress within the panic disorder market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13191&type=smp

What Trends Will Shape the Panic Disorders Market Through 2029 and Beyond?
Leading entities within the panic disorder therapeutic space are prioritizing the creation of sophisticated pharmacological agents, exemplified by sustained-release capsules, as a means to solidify their current market standing. These slow-release oral formulations are designed to dispense their therapeutic component gradually over an extended duration, commonly spanning twelve or twenty-four hours, which is beneficial for ailments necessitating consistent, long-term drug administration. A concrete illustration of this trend is the May 2023 achievement by Granules India Ltd., an Indian pharmaceutical corporation, which secured the necessary Abbreviated New Drug Application (ANDA) clearance from the United States Food & Drug Administration (USFDA) for its version of Venlafaxine hydrochloride sustained-release capsules; this product mirrors the performance characteristics of the originator drug, Effexor XR Extended-Release Capsules, produced by Upjohn US 2 LLC, by demonstrating therapeutic sameness. These Venlafaxine HCl extended-release capsules are indicated for treating various conditions, including generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD), functioning by boosting the brain's supply of serotonin and norepinephrine, with standard initial dosing typically set at seventy-five milligrams daily, subject to upward titration prescribed by a physician based on patient response.

What Are the Main Segments in the Panic Disorders Market?
The panic disordersmarket covered in this report is segmented -

1) By Type: Agoraphobia; Social Anxiety Disorder (SAD); Obsessive-Compulsive Disorder (OCD); Bipolar Disorder; Post-Traumatic Stress Disorder (PTSD); Major Depressive Disorder
2) By Treatment: Medication; Beta Blockers; Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs); Benzodiazepines; Anti-Epilepsy; Other Treatments
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administrations
4) By End Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores

Subsegments:
1) By Agoraphobia: Situational Agoraphobia; Non-Situational Agoraphobia
2) By Social Anxiety Disorder (SAD): Performance Anxiety; Generalized Social Anxiety
3) By Obsessive-Compulsive Disorder (OCD): Contamination OCD; Harm OCD; Checking OCD; Symmetry OCD
4) By Bipolar Disorder: Bipolar I Disorder; Bipolar II Disorder; Cyclothymic Disorder
5) By Post-Traumatic Stress Disorder (PTSD): Acute PTSD; Chronic PTSD; Complex PTSD
6) By Major Depressive Disorder: Recurrent Major Depressive Disorder; Single Episode Major Depressive Disorder

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13191&type=smp

Which Top Companies are Driving Growth in the Panic Disorders Market?
Major companies operating in the panic disorders market report are F. Hoffmann-La Roche Ltd., Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Baxter Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., H. Lundbeck A/S, Shionogi & Co Ltd., Recordati S.p.A, Neurocrine Biosciences Inc., Neuraxpharm, Actavis Plc., Noven Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., VistaGen Therapeutics, Valeant Pharmaceuticals International Inc., LIFECARE NEURO PRODUCTS LTD.

Which Regions Will Dominate the Panic Disorders Market Through 2029?
North America was the largest region in the panic disorders market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the panic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13191

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.